Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (ASX:PIQ) subsidiary, OxiDx, has secured a patent across 19 major European countries for its platform technology designed to assess oxidative stress
- Oxidative stress has diverse applications, ranging from an athletic monitoring tool for competition readiness and injury prevention in professional sports and horse racing industries
- The OxiDx test, utilising a simple fingerprick blood sample to detect protein biomarkers, can measure levels of muscle damage
- PIQ last traded at 98 cents
Proteomics International Laboratories (ASX: PIQ) has announced that its subsidiary, OxiDx, has secured a patent across 19 major European countries for its platform technology designed to assess oxidative stress.
“It is exciting to see the uniqueness of the OxiDx technology being recognised in leading markets, and we look forward to the technology rolling out,” PIQ Managing Director Dr Richard Lipscombe said.
OxiDx Test
Oxidative stress is implicated in more than 70 health conditions, with individual levels often serving as indicators of one’s health and fitness.
In 2019, Australia spent $1.4 billion treating potentially avoidable sports injuries.
The ability to measure oxidative stress has diverse applications, ranging from an athletic monitoring tool for competition readiness and injury prevention in professional sports and horse racing industries to a health and well-being monitoring tool.
It can also serve as a complementary diagnostic (CDx) test for assessing treatment effectiveness and precision medicine.
The OxiDx test involves a finger-prick blood sample to detect protein biomarkers, and measure the level of muscle damage. In professional sports, muscle injuries account for up to 55 per cent of all injuries, and in the horse racing industry, 85 per cent of thoroughbreds experience at least one injury in their first 2-3 years of racing.
European patent
The European patent, numbered 3775927 and titled ‘Methods for measuring relative oxidation levels of a protein’, is valid until March 2039, following the recent patent approval in Japan on 4th September 2023.
These patents are part of a broader family of patent applications across major jurisdictions, if granted they will enhance the longevity and regional coverage of OxiDx’s existing intellectual property portfolio.
PIQ last traded at 98 cents.
